Cancer Clinical Trial
Official title:
Compassionate Treatment of Advanced Cancer With Amplitude-Modulated Electromagnetic Fields
Following the discovery of tumor-specific frequencies in patients with advanced cancer, compassionate treatment with tumor-specific frequencies administered at levels that are significantly below the levels generated by cell phone will be offered to patients with limited therapeutic options.
We have previously shown that the intrabuccal administration of low and safe levels of
electromagnetic fields, amplitude-modulated at a frequency of 42.7 Hz by means of a
battery-powered portable device modifies the electroencephalographic activity of healthy
subjects (1, 2) and is associated with subjective and objective relaxation effects (3).
These results prompted us to study the effects of the 42.7 Hz frequency in patients
suffering from insomnia. A randomized control trial did not reveal any difference between
42.7 Hz treatment and placebo (4) but sequential administration of four insomnia-specific
frequencies, including 42.7 Hz, resulted in a significant decrease in sleep latency and a
significant increase in total sleep time in patients suffering from chronic insomnia (5).
Dosimetric studies have shown that the amount of electromagnetic fields delivered to the
brain of patients with this approach is 100 to 1000 times lower than the amount of
electromagnetic fields delivered by handheld cellular phones and do not result in any
heating effect within the brain (4). The U.S. FDA has determined that such a device is not a
significant risk device. Lastly, a long-term follow-up survey of 807 patients who have
received this therapy revealed that the rate of adverse reactions were low and were not
associated with increases in the incidence of malignancy or coronary heart disease (6).
Given the advantageous safety profile of athermal, non-ionizing radiofrequency
electromagnetic fields and the emerging evidence that low levels of electromagnetic or
electric fields may modify the growth of tumor cells (7-9), we decided to test the
hypothesis that low levels of electromagnetic fields modulated at tumor-specific frequencies
may alter the growth of human malignancies. We have developed a novel patient-based
biofeedback method with the goal to identify cancer-specific frequencies and have examined
patients with this approach. Following identification of such frequencies in a total of 163
patients, we will offer compassionate treatment to 28 patients with advanced cancer and
limited palliative therapeutic options.
;
N/A
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
| Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
| Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
| Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
| Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
| Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
| Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
| Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
| Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
| Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
| Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
| Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
| Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
| Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
| Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
| Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
| Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
| Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|
||
| Recruiting |
NCT05318196 -
Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
|